Finasteride Tablet, Film Coated
Product Images NDC 17856-0090

6 FDA label images from Atlantic Biologicals Corps · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 17856-0090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corps, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

17856 0090 01 Label

17856 0090 01 Label
Packaging label for Finasteride 5 mg film-coated tablets. The label shows the product NDC 17856-0090, quantity of 100 tablets, and indicates the oral dosage form. It includes storage instructions (20° to 25°C, protect from light), batch and expiration details, and contact information for the labeler Atlantic Biologicals Corp.*
FDA Label Image

Structure (Finasteride Fig 1)

Structure (Finasteride Fig 1)
Chemical structure of finasteride, the active ingredient in Finasteride 5 mg film-coated tablets by Atlantic Biologicals Corps. The diagram shows the molecular arrangement of finasteride with labeled functional groups.*
FDA Label Image

Image Of Figure 1 (Finasteride Fig 2)

Image Of Figure 1 (Finasteride Fig 2)
A line graph showing the mean change from baseline ± 1 standard error over four years comparing Finasteride and placebo. The x-axis represents time points from baseline through year 4, and the y-axis shows mean change values. Finasteride demonstrates a larger decrease over time compared to placebo, indicating a greater effect. Sample sizes for each time point are listed below the x-axis for both groups.*
FDA Label Image

Image Of Figure 2 (Finasteride Fig 3)

Image Of Figure 2 (Finasteride Fig 3)
A line graph comparing the cumulative percentage of patients over 48 months between Finasteride and placebo groups. The x-axis represents observation time in months, and the y-axis represents the percent of patients. The graph includes tabulated data below showing the number of events and patients at risk per year for both groups.*
FDA Label Image

Image Of Figure 3 (Finasteride Fig 4)

Image Of Figure 3 (Finasteride Fig 4)
A line graph showing the mean percent change from baseline plus one standard error over four years for two groups: placebo and finasteride. The x-axis represents time points from baseline to year 4, and the y-axis shows percent change. The graph illustrates differing trends between the placebo group, which declines over time, and the finasteride group, which shows improvement or stability.*
FDA Label Image

Image Of Figure 4 (Finasteride Fig 5)

Image Of Figure 4 (Finasteride Fig 5)
A line chart comparing the percent of events over 5.5 years from randomization among four groups: Placebo, Finasteride, Doxazosin, and Combination. The y-axis represents percent with event, ranging from 0 to 25%, and the x-axis shows years from randomization, ranging from 0 to 5.5 years. Placebo has the highest event rate, followed by Finasteride, Doxazosin, and Combination groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.